Uncovering the hidden value in CLM

28th January 2015

Uncovering the hidden value in CLMJacky Law

Jacky Law reports on why so many companies are struggling to activate closed-loop marketing and how content management systems can help.The thinking behind closed-loop marketing (CLM) was always deceptively simple.... Read more

Does real world evidence matter in Health Technology Assessments?

27th January 2015

Does real world evidence matter in Health Technology Assessments?Daniel Liden, Ashley Jaksa, Yin Ho

Health Technology Assessment (HTA) agencies usually rely on randomised controlled trials for clinical data when evaluating drugs, but these do not always tell the entire story. Both biopharmaceutical companies and... Read more

The role an unmet need plays in driving innovation

26th January 2015

The role an unmet need plays in driving innovationCassandra Rix

As healthcare budgets tighten and patients' expectations increase, pharma must go beyond simply supplying the pills and work to provide services and technologies that address broader unmet needs.Historically, pharma innovation... Read more

Unleashing the power of data-driven medicine

23rd January 2015

Unleashing the power of data-driven medicineJurgi Camblong

Genomic data can now be analysed and used to diagnose conditions and tailor treatments to individual patients, but concerns over broader data sharing and security need to be overcome for... Read more


Momentum building behind tau as Alzheimer's target

28th January 2015

Momentum building behind tau as Alzheimer's targetStaff reporter

After years of playing second fiddle to amyloid as a drug target in Alzheimer's disease, there are signs of increasing interest in the development of tau protein-targeting drugs.Earlier this month,... Read more

Novartis expects 10 NME filings by end-2016

27th January 2015

Novartis expects 10 NME filings by end-2016Staff reporter

Novartis told investors today that it is entering a particularly fruitful period of product development, with 10 new molecular entities (NMEs) due to be submitted for approval in 2015 and... Read more

Labour launches NHS election pledges

27th January 2015

Labour launches NHS election pledgesLinda Banks

One hundred days before the UK election the Labour party has launched its pledge on the NHS, promising 36,000 more staff, to revoke privatisation laws and provide a further 5,000... Read more

Genzyme extends Gaucher disease options in Europe

26th January 2015

Genzyme extends Gaucher disease options in EuropeLinda Banks

The European Commission (EC) has granted marketing authorisation for Genzyme's orphan drug Cerdelga (eliglustat), a first-line oral therapy for adults living with Gaucher disease type 1 (GD1).The drug was licensed... Read more

Audio & Video

Live Tweetchat: Managing COPD in the rea…


Working in partnership, Atlantis Healthcare and pharmaphorum present a Tweetchat focussed on the real world challenges patients face in managing their COPD,... View more

Live webinar/debate - Feb 4th - COPD, co…

Join the COPD webinar/debate



COPD is a widespread, costly and largely preventable condition which affects over 300 million people worldwide and is recognised... View more

On demand webinar: The Price is Right? -…



With challenges to highly priced rare disease medicines and the Cancer Drug Fund evolving again – what is next, what are the... View more

Now on demand - real world insight into …

The Diabetes Debate


Now available on demand (free to access) - originally broadcast on October 29th 2014.

Non-adherence to self-management regimens in diabetes is globally... View more

White Papers

Computer Gaming: The Future of Decision-…

Computer Gaming: The Future of Decision-Making for Life Sciences?

How can life science brands identify winning strategic decisions when there are so many variables to consider? One route is via 'road-testing' decisions ahead of sign-off under computer game simulated... View info

How do doctors want to engage with pharm…

How do doctors want to engage with pharma on new products?Dr Tim Ringrose

With more than 80 per cent of European doctors saying they want to stay abreast of new developments about pharmaceutical products, it is important to understand how they wish to... View info

Modelling patient behaviour to improve s…

Modelling patient behaviour to improve self-management in diabetesDr Sinéad NíMhurchadha & Jeremy Sayers

An understanding of health psychology is essential to helping patients adhere to their medication and lifestyle regimens. This report hones in on how the COM-B model of behaviour provides a... View info

"The future ain’t what it used to b…

"The future ain’t what it used to be"Paul Stuart-Kregor

Preparation is key to creating and maintaining a strong drugs pipeline. However, the statistics demonstrate that successful product commercialisation strategies are not always implemented. Products are developed for which there... View info

Further News & Articles

Regeneron/Sanofi in pole position for PCSK inhibitor launch

Sanofi and Regeneron could have approval for their new cholesterol-lowering drug alirocumab in the US before the... Read more


Bayer’s Xarelto makes grade in NICE final draft guidance

In final draft guidance UK health watchdog NICE has confirmed its earlier positive draft decision recommending B... Read more


Novo Nordisk gets CHMP backing for obesity drug Saxenda

Novo Nordisk has won a Committee for Medicinal Products for Human Use (CHMP) endorsement for a higher-dose ve... Read more


Cancer Drugs Fund: winners and losers in pharma, but a long-term fix is needed

Roche to pioneer 'multi-indication pricing' for Avastin – is this part of a future solution?

Last... Read more


T cell specialist Autolus launched with £30 million warchest

A new biopharma company spun out of University College London (UCL) is planning to make waves in T cell thera... Read more


New immunotherapies march ahead

Following approval in Europe this week, Novartis' Cosentyx (secukinumab) has now been given the go-ahead in the ... Read more